Multiplexed Diagnostics Market: By Product (Reagents and Consumables, Analyzers), By Application (Disease Diagnostics, Molecular Diagnostics, and Drug Development), By Technology (Very High Density Multiplexed Assays, High Density Multiplexed Assays, Medium Density Multiplexed Assays, Low Density Multiplexed Assays, and Next Generation Sequencing Assays), By End User (Hospitals, Diagnostic Centers, and Research Centers), and Geography   

Purchase Option

$ 3000
$ 4400
$ 6600
$ 8900

Multiplexed Diagnostics Market size was valued at USD 8,921.4 million in 2021, growing at a CAGR of 16.2% from 2022 to 2028. The global market provides a detailed overview and that can be segmented by product, by application, and by end user. By product, the global multiplexed diagnostics market has been segmented into Reagents and Consumables and Analyzers. The Reagents and Consumables segment is likely to be the largest and fastest-growing segment in terms of type in 2021 and is expected to maintain the trend in the forecasted years. Based on application, the global multiplexed diagnostics market is segmented into Disease Diagnostics, Molecular Diagnostics, and Drug Development), By Technology (Very High-Density Multiplexed Assays, High Density Multiplexed Assays, Medium Density Multiplexed Assays, Low Density Multiplexed Assays, and Next Generation Sequencing Assays. Among these, the Molecular Diagnostics segment is expected to have the fastest-growing market during the forecast period 2022-2028. Based on end user, the global multiplexed diagnostics market is segmented into Hospitals, Diagnostic Centers, and Research Centers. Hosted segment is the second-largest share during the forecast period 2022-2028. Multiplexed Diagnostics are utilized as a part of examination of biological samples, which are fit for finishing a screening procedure with a solitary run. Multiplexed assay tests are engaged with the discovery and analysis of various illnesses and contaminations, which incorporate growths, immune system ailments, hypersensitivities, and cardiovascular infections. Key Development: In Oct 2022, Genes2Me launched Rapi-Q- Point of Care RT PCR for diseases like HPV and Tuberculosis. In Oct 2022, Multi-omics Startup Pleno Inc. announced $40 Million in series a funding led by deerfield management with participation by foresite capital.

Global Multiplexed Diagnostics Market Summary

Study Period

2023-29

Base Year

2022

CAGR

16.2%

Largest Market

North America

Fastest Growing Market

Europe
Multiplexed Diagnostics Market Dynamics

Growing incidence of various types of cancers and infectious diseases are anticipated to propel the market growth over the forecast years.

Key Features of the Reports

  • The report provides granular level information about the market size, regional market share, historic market (2018 to 2022) and forecast (2023 to 2029)
  • The report covers in-detail insights about the competitors overview, company share analysis, key market developments, and their key strategies
  • The report outlines drivers, restraints, unmet needs, and trends that are currently affecting the market
  • The report tracks recent innovations, key developments and startup’s details that are actively working in the market
  • The report provides plethora of information about market entry strategies, regulatory framework and reimbursement scenario
  • The report analyses the impact of socio-political environment through PESTLE Analysis and competition through Porter’s Five Force Analysis in addition to recent technology advancements and innovations in the market

Global Multiplexed Diagnostics Market Segmentation

By product
  • Reagents and Consumables
  • Analyzers
By Technology
  • Very High Density Multiplexed Assays
  • High Density Multiplexed Assays
  • Medium Density Multiplexed Assays
  • Low Density Multiplexed Assays
  • Next Generation Sequencing Assays
By Application
  • Disease Diagnostics
  • Molecular Diagnostics
  • Drug Development
By End User
  • Hospitals
  • Diagnostic Centres
  • Research Centres

Frequently Asked Questions

The fastest-growing segment of the global multiplexed diagnostics market is Molecular Diagnostics due to its various applications and high demand.

The personalized medicines and genomics are recent trends in the market that will create lots of opportunity in the global market.

The unavailability of specific COVID and other infectious diagnostic kits will create lucrative opportunity in the global market.

The shortage of skilled technician and high cost associated with multiplexed diagnostics may hamper the global market growth.

[urltag url='request-table-of-content']

  • Thermo Fisher Scientific, Inc. (U.S.)
  • QIAGEN N.V. (Netherlands)
  • Luminex Corporation (U.S.)
  • Bio-Rad Laboratories(U.S.)
  • Illumina, Inc. (U.S.), Inc.